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tivity reported (p < 0.001). 31.8% of the population with very
sensitive skin, 18.7% with sensitive skin, 7.0% with slightly
sensitive skin and 5.1% with non sensitive skin also presented
with a dermatological condition. Those with dermatosis more
frequently reported sensitive or very sensitive skin (64.9% versus
26.8%, p < 0.001). A history of childhood atopic dermatitis or
eczema was more frequent in patients with sensitive or very
sensitive skin (20.7% versus 8.9%, p < 0.001). The interviewees
who declared that they had dry or oily skin also signiﬁcantly more
frequently (p < 0.001) reported sensitive or very sensitive skin
than those with normal skin. CONCLUSIONS: This is the ﬁrst
study of sensitive skins to be conducted in a representative Swiss
population. Thus, slightly less than two million Swiss would
appear to have sensitive or very sensitive skin. This is probably a
much higher ﬁgure than the population spontaneously reporting
this condition to a dermatologist. These specialists should there-
fore systematically ask their patients this question. The non
response rate was negligible, which indicates that the term “sen-
sitive skin” is meaningful to the immense majority of people.
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OBJECTIVES: To evaluate the perception of skin sensitivity in
Greece. METHODS: A representative nationwide sample of the
Greek population aged 15 and over was taken. The individuals
were questioned by telephone and selected as per the quotas
method.RESULTS:To the question “Do you have sensitive skin”,
23.0% of men and 37.7% of women answered “sensitive” or
“very sensitive”.Womenhad signiﬁcantlymore sensitive skin than
men (p < 0.001). The no response rate was less than 3%. A total
of 37.2% of the population with very sensitive skin, 31.1% with
sensitive skin, 14.6% with slightly sensitive skin and 6.9% with
non sensitive skin also presented with a dermatological condition.
Those with dermatosis more frequently reported sensitive or very
sensitive skin (p < 0.001). A history of childhood atopic dermatitis
or eczema was more frequent in patients with sensitive or very
sensitive skin (17.8% versus 10.1%, p = 0.019). The interviewees
who declared that they had dry or oily skin also signiﬁcantly more
frequently (p < 0.001) reported sensitive or very sensitive skin
than those with normal skin. In addition, patients who regularly
consulted a dermatologist had signiﬁcantly more sensitive skin
(p < 0.001). Subjects with sensitive or very sensitive skin reddened
more easily for no reason (26.5% versus 10.7%, p = 0.001), after
exposure to the sun (69.8% versus 56.2%, p = 0.005) and in
response to an emotional stimulus (56.6% versus 41.5%,
p = 0.002). CONCLUSIONS: This is the ﬁrst study of sensitive
skins to be conducted in a representative Greek population. Thus,
slightly less than three million Greek people would appear to have
sensitive or very sensitive skin. This is probably a much higher
ﬁgure than the population spontaneously reporting this condition
to a dermatologist. These specialists should therefore systemati-
cally ask their patients this question. The non response rate was
negligible, which indicates that the term “sensitive skin” is mean-
ingful to the immense majority of people.
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OBJECTIVES: To evaluate the perception of skin sensitivity in
Italy. METHODS: A representative nationwide sample of the
Italian population aged 15 and over was taken. The individuals
were questioned by telephone and selected as per the quotas
method. RESULTS: To the question “Do you have sensitive
skin”, 51.5% of men versus 57.5% of women answered “sensi-
tive” or “very sensitive”. The no response rate was less than
2.0%. A total of 43.8% of the population with very sensitive
skin, 41.7% with sensitive skin, 14.6% with slightly sensitive
skin and 0.0% with non sensitive skin also presented with a
dermatological condition. Those with dermatosis more fre-
quently reported sensitive or very sensitive skin (85.4% versus
51.2%, p < 0.001). A history of childhood atopic dermatitis or
eczema was more frequent in patients with sensitive or very
sensitive skin (16.1% versus 9.0%, p = 0.021). The interviewees
who declared that they had dry or oily skin also signiﬁcantly
more frequently (p = 0.001) reported sensitive or very sensitive
skin than those with normal skin. Subjects with sensitive or very
sensitive skin reddened easily after exposure to the sun (67.9%
versus 54.8%, p = 0.003) and in response to an emotional stimu-
lus (64.0% versus 54.7%, p < 0.039). CONCLUSIONS: This is
the ﬁrst study of sensitive skins to be conducted in a representa-
tive Italian population. Thus, slightly more than 27 million Ital-
ians would appear to have sensitive or very sensitive skin. This is
probably a much higher ﬁgure than the population spontane-
ously reporting this condition to a dermatologist. These special-
ists should therefore systematically ask their patients this
question. The non response rate was negligible, which indicates
that the term “sensitive skin” is meaningful to the immense
majority of people.
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OBJECTIVES: To determine the age- and gender-speciﬁc
12-months administrative prevalence rate of psoriasis in
Germany, and to explore physician groups involved in the pro-
vision of health care services for these patients. METHODS:
Data for patients with a diagnosis of psoriasis (L40, ICD-10)
were extracted from the Nordbaden claims database, covering
the complete subpopulation insured by Statutory Health Insur-
ance (2.238 million lives in 2003; for comparison: total German
population insured by SHI in 2003, 70.2 million) in Nordbaden
in South-Western Germany (representing 82% of the total
regional population). Physician groups involved in health care
provision were identiﬁed. RESULTS: 44,735 patients with a
diagnosis of psoriasis were identiﬁed in Nordbaden, correspond-
ing to an overall administrative prevalence rate of 2.0% (95%
conﬁdence interval [CI], 1.98–2.02%; no difference between
males and females). Prevalence increased with age (<20 years [y],
0.56%; 20y-<40y, 1.58%; 40y-<60y, 2.62%; 60y-<80y, 3.09%),
except for individuals age 80y or older (2.41%). In the age group
20y-<40y, females were more often affected than males (1.68%
versus 1.48%), whereas in the age groups 40y-<60y and 60y-
<80y, prevalence rates were higher for males (3.37% versus
2.87% and 2.98% versus 2.21%, respectively). Most diagnoses
were reported by dermatologists (55.0% of patients), general
practitioners (46.4%) and specialists for internal medicine
(18.0%; ﬁgures include patients diagnosed by more than one
physician). Each of the other physician groups included in the
study contributed less than 2% of diagnoses. CONCLUSIONS:
To the best of your knowledge, this analysis provides for the ﬁrst
time administrative data on the prevalence of psoriasis in a
German population. Its ﬁndings appear consistent with interna-
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tional studies as well as with reports on the age of onset of
psoriasis. The data may provide a basis for future studies on
health care utilization and cost of illness associated with psoriasis
in Germany.
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OBJECTIVES: To ﬁnd out the persistence degree (period of time
of continuous therapy with the drug prescribed) of glaucoma
patients treated with prostaglandin (latanoprost, bimatoprost,
and travoprost), or b-blocker (timolol) monotherapy.
METHODS: An observational and retrospective study was con-
ducted of a 24-month follow-up in 191 patients (from 4 centers),
to examine the time elapsed until patients’ withdrawal from
therapy. The required parameters were obtained from patients’
medical records. A descriptive analysis, a Kaplan-Meier survival
analysis, and a Cox regression model were used to determine
which was the drug related to a greater persistence degree, and to
detect variables signiﬁcantly inﬂuencing persistence in these
patients. RESULTS: In both the descriptive analysis and the
survival curves, latanoprost was associated with a higher persis-
tence degree in the glaucoma treatment: 81.6% vs. 22.9% for
bimatoprost, 65.4% for travoprost and 60.5% for timolol
(p < 0.0001). The persistence degree was signiﬁcantly inﬂuenced
by the following variables: the antiglaucoma agent used as mono-
therapy, with a six-fold higher risk of treatment withdrawal
during the follow-up period due to receiving travoprost instead
of latanoprost (p < 0.0001); and the age (p = 0.001). Even
though comorbidities did not indicated to be directly related to
persistence, their occurrence was related to age. The main
reasons for treatment withdrawal were lack of efﬁcacy and the
existence of intolerance and/or adverse events, signiﬁcantly supe-
riors in the bimatoprost group, 28.6% (p < 0.001) and 48.6%
(p < 0.001), respectively. CONCLUSIONS: Latanoprost shows a
higher persistence degree compared to travoprost, bimatoprost
and timolol in routine clinical practice, resulting in a better
control of IOP and lower associated costs, improving the health
care quality of glaucomatous patients and considerable resources
saving for the National Health System.
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OBJECTIVES: Our aim was to evaluate systematically the efﬁ-
cacy and safety of tacrolimus ointment for the treatment of
adults and children with atopic dermatitis (AD). METHODS:
Electronic and manual bibliographic searches were conducted to
identify relevant prospective randomised controlled trials
(RCTs). The primary outcome measures of interest included
treatment success measured by objective clinical scales and safety,
based on the incidence of adverse events. Meta-analyses were
conducted using a ﬁxed-effect model. RESULTS: Thirty RCTs
met the inclusion criteria. Comparator treatments included
topical corticosteroids (n = 14) and 1% pimecrolimus cream
(n = 5). Eight RCTs comparing tacrolimus with corticosteroids
(paediatric, n = 1593; adult, n = 2104) provided data for meta-
analysis. In 6/8 RCTs (75%), treatment with 0.1% or 0.03%
tacrolimus was superior to corticosteroid treatment (1% hydro-
cortisone acetate, 0.1% hydrocortisone butyrate or 0.005% ﬂu-
ticasone) as measured by the Patient’s Assessment of Global
Response (‘much better’) and the Physician’s Global Evaluation
of Clinical Response (‘cleared or excellent improvement’). While
the incidence of skin burning was increased with tacrolimus
treatment in both adult and paediatric patients, levels of skin
infection, skin erythema and rash were comparable between
treatments. Data from four trials comparing tacrolimus ointment
with 1% pimecrolimus cream were suitable for inclusion in meta-
analysis (paediatric, n = 793; adult, n = 731). From week three of
treatment onwards, tacrolimus at both doses was superior to
treatment with 1% pimecrolimus cream in both paediatric and
adult populations. Considering safety, the incidence of skin infec-
tion, pruritis, erythema and pain were comparable between treat-
ments. CONCLUSIONS: In the majority of included RCTs,
tacrolimus ointment at a dose of 0.03% or 0.1% demonstrates
superior efﬁcacy compared with corticosteroids or 1% pimecroli-
mus cream in the treatment of both paediatric and adult AD
patients. Adverse events were predictable in nature and with the
exception of skin burning did not differ between treatments.
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OBJECTIVES: To investigate the comparative incidence of
hyperaemia of all prostaglandin glaucoma treatments in avail-
able randomised controlled trials (RCTs). METHODS: A sys-
tematic review searching MEDLINE, EMBASE, Cochrane
Central and conference proceedings until March 2007 for RCTs
of adults with primary open-angle glaucoma (POAG) and/or
ocular hypertension (OH) receiving prostaglandin treatment.
Active comparison parallel RCTs longer than three months were
included. Results were pooled through ﬁxed effects meta-
analyses. RESULTS: We found 13 RCTs (7 for each prostaglan-
din comparison) including 2364 patients in total. The median
duration of trials was 19.5 weeks (range: 12–52 weeks). The
average incidence of hyperaemia was 35% (95% CI: 33%–37%)
in patients receiving prostaglandin treatments (travoprost and
bimatoprost = 44%, latanoprost = 27%). Comparing bimato-
prost versus latanoprost, the pooled risk ratio using ﬁxed effects
models for having hyperaemia was 1.83 (95% CI: 1.54–2.18),
travoprost vs. latanoprost was 1.52 (95% CI: 1.28–1.79);
bimatoprost v.s. travoprost was 1.23 (95% CI: 1.03–1.46). These
equate to one more case of hyperaemia for every 5 patients
treated with bimatoprost rather than latanoprost, every 6 treated
with travoprost rather than latanoprost, and every 8 treated with
bimatoprost rather than travoprost. Sensitivity analysis using a
random effects model did not alter the ﬁndings. Of the included
RCTs, eight reported hyperaemia severity on a discrete scale of
0 to 3, with some reporting additional increments of 0.5. The
variability in scales and statistics reported prevented meta-
analysis of these data. CONCLUSIONS: Hyperaemia was
common, affecting more than a third of patients treated with
prostaglandins. However, there is a lack of consistent reporting
among RCTs to address its burden. Compared to latanoprost
treated patients, bimatoprost and travoprost incurred an addi-
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